


**Westminster Health Forum policy conference:
Next steps for tackling antimicrobial resistance in the UK**

Timing: Morning, Tuesday, 21st April 2026

Taking place online



WESTMINSTER
HEALTH FORUM

Draft agenda subject to change

- 8.30 Registration
- 9.00 **Chair's opening remarks**
Dr Danny Chambers MP
- 9.05 **Assessing the current state of antimicrobial resistance and next steps for developing surveillance and preparedness**
Dr Colin Brown, Head, Antimicrobial Resistance and Healthcare Associated Infections, and Deputy Director, Epidemic and Emerging Infections, UK Health Security Agency
Questions and comments from the floor
- 9.30 **Enhancing prevention, targeted prescribing and workforce education**
prescribing in primary care, online-first and private prescribing settings | reducing reliance on antimicrobials | unintended exposure, infection prevention and control practice | community pharmacy and reducing unnecessary antimicrobial use | strengthening workforce education and public awareness | digital health tools for prescribing, and infection prevention and control | developing and scaling innovations in detection, diagnosis and outbreak response | tackling infection burden inequalities | priorities for supporting patients impacted by AMR | implications from the National Audit Office's work on AMR and expectations for performance monitoring and progress review
Dr Sheikh Mateen Ellahi, GP Partner, Elm Tree Medical Centre
Dr David Jenkins, Vice President, British Society for Antimicrobial Chemotherapy
Dr Paula Sommer, Head of Research Awards and Partnerships, Cystic Fibrosis Trust
Ravi Chana, Executive Director, Diagnostics, Association of British HealthTech Industries
Melody Chapman, Senior Medicines Optimisation Lead Pharmacist, NHS Frimley
Questions and comments from the floor
- 10.20 **Next steps for embedding stewardship across hospital and community care and alignment with the 10 Year Health Plan**
Professor Matt Inada-Kim, National Clinical Director, Infection Management and Antimicrobial Resistance, NHS England
Questions and comments from the floor
- 10.45 **Chair's closing remarks**
Dr Danny Chambers MP
- 10.50 Break
- 11.00 **Chair's opening remarks**
Baroness Bennett of Manor Castle
- 11.05 **Strengthening the UK's position as a leader in antimicrobial resistance policy - international partnerships and financial models**
Peter Howitt, Policy Lead, Fleming Initiative
- 11.15 **'Animal health: priorities and challenges in mitigating the risk of AMR in animals'**
Dr Kitty Healey, Head, Antimicrobial Resistance, Veterinary Medicines Directorate
- 11.25 Questions and comments from the floor
- 11.45 **'Supporting AMR innovation with regulatory science'**
Dr Carmen Coxon, Regulatory Scientist, Medicines and Healthcare products Regulatory Agency
- 11.55 **Advancing antimicrobial innovation - incentives, clinical development and emerging technologies**
assessing the UK Antimicrobial Products Subscription Model and its impact on investment and access | strengthening investor confidence | international push and pull incentive models | innovation alongside stewardship | market approval and routes to adoption | whole-genome sequencing in product development and surveillance | alignment of global and UK regulatory approaches, including updated clinical trial frameworks | opportunities for AI in accelerating research | streamlining access to alternative therapies, including phage-based medicines | infrastructure to support rapid diagnostic tools | implications from the Life Sciences Sector Plan for research, innovation and commercial development
Professor Christopher Dowson, Professor, Microbiology, University of Warwick
Professor Colm Leonard, Chief Clinical Officer and Chair, Clinical Development Committee, INFEX Therapeutics
Dr Beverley Isherwood, PACE Director and Strategy Leader, Infectious Diseases, Medicines Discovery Catapult
Professor Matt Holden, Professor, Pathogen Genomics, University of St Andrews; and Head, Genomics, Public Health Scotland
Professor Catrin Moore, Professor, Infectious Diseases and Vaccinology, St George's University of London
- 12.20 Questions and comments from the floor
- 12.45 **Next steps for the Antimicrobial Products Subscription Model**
Dr Nick Crabb, Chief Scientific Officer, National Institute for Health and Care Excellence
Questions and comments from the floor
- 13.10 **Chair's and Westminster Health Forum closing remarks**
Baroness Bennett of Manor Castle
Tess Mitchell-Thomas, Westminster Health Forum